GSK PLC closed 25.31% below its 52-week high of £18.24, which the company reached on May 16th.

Pharma with 3,615 puts trading, or 1.6x expected. Most active are May-25 30 puts and Aug-25 35 puts, with total ...

The lawsuit alleged that Pfizer’s RSV vaccine, Abrysvo, violated GSK's patent rights in its competing RSV vaccine Arexvy. The companies said they would dismiss the case “with prejudice,” preventing it ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

Employee well-being is now a key priority in the modern workplace. Transparent employee monitoring tools, when used ethically, offer valuable insights into workload imbalances and early signs of ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSE: GSK) for violations of ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-based pharmaceutical giant GSK plc in a deal expected ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier. GSK is fronting £38.5 million (nearly $50 million), in a partnership with ...

South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK (LSE: GSK) to develop novel medicines for neurodegenerative diseases by ...

Narrowing down the right stocks to buy based on multiple metrics is almost impossible without a solid methodology – which is where InvestingPro comes in. Our top stock picks for this month are ...